- Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
- Devonian Health Group Announces the Appointment of New Board Members and Grant of Stock Options
- Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
- Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
Arcturus Therapeutics Holdings Inc (ARCT:NMQ) closed at 28.48, -15.74% below its 52-week high of 33.80, set on May 11, 2023.
11.70Jun 16 202233.80May 11 2023
Short selling activityProvided by S&P Global Market Intelligence
|Market cap||710.56m USD|
|EPS (TTM)||3.75 |
Data delayed at least 15 minutes, as of Jun 07 2023 21:00 BST.